Recursion Pharmaceuticals (RXRX) Could Be 45% Below Fair Value As Earnings Near
Recursion Pharmaceuticals (RXRX) is back in focus after a 4.95% slide to US$4.03 ahead of its Q3 2026 earnings release, where analysts expect higher year over year EPS and revenue.
The latest pullback comes after a mixed stretch, with a 7 day share price return of 8.78% and a 90 day gain of 34.17% offset by a year to date decline of 4.17% and a 1 year total shareholder return that is down 27.08%. This points to short term momentum rebuilding, while longer term holders remain deep in the red.
Scan how Recursion Pharmaceuticals compares with other high growth healthcare AI plays by checking the hand picked list of 34 healthcare AI stocks before earnings hit the tape.
After that sharp swing, Recursion Pharmaceuticals now asks a simple question of investors: Do the current risks justify paying up for the potential, or does the recent rebound already capture most of the upside on offer?
Most Popular Narrative: 45% Undervalued
Recursion Pharmaceuticals last closed at $4.03 while the most followed valuation story pegs fair value at $7.32. That gap puts the spotlight on whether the platform and pipeline can live up to what the narrative is pricing in over time.
Further monetization of large pharma collaborations, including the Sanofi immunology candidate that carries more than US$300 million in remaining milestones and low double digit royalties, and Roche or Genentech programs with roughly US$300 million per program in economics, can provide recurring non dilutive cash inflows that support revenue and reduce pressure on net margins.
See why 143 investors see Recursion Pharmaceuticals as 45% undervalued.
Result: Fair Value of $7.32 (UNDERVALUED)
Still, the Recursion Pharmaceuticals story can change quickly if milestone payments slip again or if continued losses and fresh share issuance keep weighing on per share value.
Find out about the key risks to this Recursion Pharmaceuticals narrative.
Another View: Recursion Pharmaceuticals Looks Expensive On Sales
Recursion Pharmaceuticals screens as undervalued on fair value estimates, yet its current P/S ratio of 43.9x is very high compared with the US Biotechs industry at 11.3x and peers at 16.4x, and the fair ratio sits at 0x. That kind of gap can mean real valuation risk if sentiment cools.
For a closer look at how this pricing stacks up against the underlying numbers, and what that might mean for future returns, See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Mixed signals around Recursion Pharmaceuticals can be confusing, and the market rarely waits for late decisions. Take a moment to weigh both sides of the ledger and review its 2 key rewards and 3 important warning signs.
Looking for more Recursion Pharmaceuticals sized opportunities?
Do not stop your research with Recursion Pharmaceuticals alone, because a wider watchlist can help you spot ideas before the crowd fully tunes in.
- Target resilient cash generators by scanning companies with sturdy finances and low risk profiles through the list of solid balance sheet and fundamentals (24 results).
- Hunt for value where quality and price still line up by reviewing the 33 high quality undervalued stocks.
- Broaden your opportunity set beyond the usual tickers and see what quietly strong businesses are hiding in the 19 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com